



KICK-OFF MEETING

Seville, February 21&22 2019

Horizon 2020 Call - Topic: SC1-BHC-18-2018

Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC)

Project Acronym: SELNET – GA 825806

Purpose: SELNET Kick off meeting

Venue: Instituto de Biomedicina de Sevilla (IBiS). Calle Antonio Maura Montaner, 41013 Sevilla.
(link to Google Maps: <https://goo.gl/maps/tdkMJQC4uwp>)

Meeting rooms: All sessions will be held in the Ground floor

DAY 1. SELNET CONSORTIUM

09:00-09:15 INTRODUCTION

Javier Martin Broto *Outlining the aim and frame of the project (15)*

09:15-10:30 SELNET CONSORTIUM COUNCIL MEETING

09:15-09:40 Administrative procedures (P1-SAS)

09:40-10:05 Financial aspects: Budget, Milestones and Procedures (P1-SAS)

10:05-10:30 Overview of Activities, Ethics requirements WP1 and Project Management WP10 (P1-SAS)

10:30-13:30 WORK PACKAGES (Chairman Scientific Project Manager): Objectives, Timing, Development Plan and Publications goals.

10:30-10:55 WP 2: Definition of reference centers (P2-INT)

10:55-11:20 WP 3: Analysis of healthcare barriers (P5-INCAM)

11:20-11:45 WP 4: Clinical practice guidelines (P4-CLB)

11:45-12:00 WP 5: Continuing medical education (P1-SAS)

12:00-12:25 WP 6: Multidisciplinary review of clinical cases (P1- SAS)

12:25-12:50 WP 7: Clinical management quality study (P10-GEIS)

12:50-13:15 WP 8: Translational research program (P1-SAS)

13:15-14:15 Lunch

14:15-14:50 WP 9: Dissemination and exploitation of results (P7-IAF/P11-SPAEN)

14:50-15:35 MANAGEMENT & GOVERNANCE

14:50-15:15 Project Coordinator

15:15-15:35 SELNET Consortium Steering Committee (SCSC) role and functioning
External Monitoring Committee (EMC)
Ethics Board (EB)

15:35-16:00 Coffee break

16:00-16:40 STAKEHOLDERS AND INTERACTION PLANS

16:00-16:20 ISG, FSG and GEIS cooperative groups

16:20-16:40 EURACAN



16:40-17: 10 H2020 FUNCTIONING – CELAC PARTNERS
Annotated Model Grant Agreement
Webpages: Participant Portal and Online Manual



SELNET MEETING

Seville (Spain), February 22nd, 2019

SCIENTIFIC PROGRAMME

Coffees & Welcome 8:00

BLOCK 1 Chairpersons: E Ortiz & A Righi 8:30-10:00 H

- 1.- Pathology in the era of NGS analyses. When molecular ancillary tests are needed (E De Álava, Spain 15')
- 2.- Neoadjuvant chemotherapy in localized high-risk STS of Extremities/Trunk wall (J Martín Broto, Spain, 15')
- 3.- First-line choices in advanced STS (M Chacón, Argentina 15')
- 4.- Second-line options in advanced STS (N Hindi, Spain 15')

Discussion time: 20'

BLOCK 2 Chairpersons: C Valverde & N Jiménez (Costa Rica) 10:00- 11:30

- 5.- Targeted therapies in rare STS (C Mello, Brazil 15')
- 6.- Intermediate Aggressive Subtypes: Desmoid Tumors, PVNS and GCTB (JL Martinez, Mexico 15')
- 7.- Unmet aspects in
 - Angiosarcoma (A Dufresne, France 15')
 - Extraskelatal Myxoid Chondrosarcoma (S Brich, Italy 15')
 - Solitary Fibrous Tumors (D Moura, Spain 15')

Discussion time: 15'

BREAK BRUNCH 11:30-12:00

BLOCK 3 Chairpersons: M Calderón (Perú) & A Dufresne 12:00-13:00

- 8.- Treatment options beyond 1st line in osteosarcoma (recurrent non-resectable tumors) (E Palmerini, Italy 15')
- 9.- Upcoming systemic treatments in GIST (C Serrano, Spain 15')

Discussion time: 15'

- 10.- Clinical Case: presentation and discussion (D Collado, Spain 15')

FAREWELL J Martin-Broto

LUNCH